Similar to the studies of the same kind [18], rectal cancer patients harboring p53 mutations showed a reduced sensitivity compared to patients lacking p53 or those with wild–type p53 (Fig. 6D and Table 2). This evidence concerns the gene TP53 and rectal cancer.